During Magnetic Resonance Imaging (MRI) procedures, contrast agents are typically administered through intravenous injection to improve the clarity of images, especially when it comes to identifying cancers. However, these agents can increase costs, extend the duration of examinations, and may also produce side effects such as allergic reactions and kidney strain because they contain the heavy metal gadolinium.

In a recent interview with Ming Pao, Professor Cai Jing, Head of the Department of Health Technology and Informatics at PolyU, shared insights into his research on a new AI-powered MRI solution that eliminates the need for contrast agents.

As a co-founder of the PolyU startup MedVision Limited, Professor Cai led the research team that developed the new Contrast-Free Virtual Enhancement MRI System. The AI model was trained using thousands of MRI images from nasopharyngeal cancer patients, collected from a network of 39 hospitals across Hong Kong, Macao, Guangdong, Shanghai, and Sichuan, encompassing variety of MRI brands.

Professor Cai envisions this AI technology as a potential replacement for conventional contrast agents, offering improved diagnostic clarity while reducing costs and side effects. The system also preserves patient autonomy by offering them the choice to use or forgo contrast agents in their treatment decisions.

The innovation has already gained recognition, securing patents in the US and Mainland China, as well as multiple innovation awards. MedVision Limited is in negotiations to commence clinical trials in the first quarter of this year.

Read the full interview (Chinese version only).

Discover more about Contrast-Free Virtual Enhancement MRI System.